PE-22-28 vs Adamax
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: PE22-28, Spadin Analog
PE-22-28 is a seven-amino-acid peptide that blocks a potassium channel in the brain called TREK-1, the same target tied to depression. It is a shortened, more potent and more stable version of spadin, a natural fragment cut from the sortilin propeptide, and it was built to act like a fast antidepressant. All evidence is from rodents. There are no human clinical trials.
Also: Semax derivative
Adamax is sold widely as an enhanced Semax derivative, and it is one of the clearest examples of a compound where availability has run far ahead of information. Vendors list it, forums discuss it, and there is essentially no peer-reviewed literature under this name. This page tells you what is actually known, what is inferred from its parent compound, and where the honest gaps are, because pretending otherwise would not help you.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | PE-22-28 | Adamax |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | PE-22-28 inhibits TREK-1, a two-pore-domain potassium channel that normally lets potassium leak out of neurons and quiets them down. Block that leak and serotonin-producing neurons in mood-related regions become easier to fire, which is the proposed antidepressant mechanism. This is the same pathway implicated in why TREK-1 knockout mice show a depression-resistant phenotype. Compared to the parent peptide spadin, PE-22-28 binds TREK-1 far more tightly and survives much longer in the body, which is why it was developed. Whether TREK-1 blockade translates into a real antidepressant effect in people remains unproven. | What is claimed is that Adamax is a structurally modified Semax analog, with modifications intended to improve stability and blood-brain barrier penetration relative to Semax itself. Semax is a synthetic fragment of ACTH (4-10) developed in Russia, and its best-supported mechanism is upregulation of BDNF and NGF in the hippocampus and cortex, alongside modulation of the monoamine systems and some effect on the melanocortin pathway. If Adamax is what it is sold as, its mechanism should be broadly that of Semax with altered pharmacokinetics. That is a reasonable inference and it is not the same thing as a demonstrated mechanism. No published pharmacology characterises Adamax specifically. |
| Common Dosing | 100-300 mcg intranasal or subcutaneous Once daily | 100-300 mcg daily (intranasal) Once daily, morning |
| Administration | Intranasal or subcutaneous injection | Intranasal is the most commonly reported route, following Semax practice. Subcutaneous is also reported. |
| Typical Duration | Research protocols vary, often 2-4 weeks | Community protocols typically report 2-4 week blocks rather than continuous use |
| Best Time to Take | Morning | Morning |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The core data come from a single 2017 paper by Djillani and colleagues in Frontiers in Pharmacology, which screened shortened spadin analogs and found PE-22-28 to be the standout: dramatically stronger TREK-1 inhibition, longer in vivo stability, and antidepressant-like behavior in mice using standard tests like the forced swim and novelty-suppressed feeding paradigms. The same line of work reported that short treatment courses increased hippocampal neurogenesis in rodents, which the authors framed as a possible mechanism for faster mood effects than conventional SSRIs. The broader TREK-1 and spadin story traces back to Mazella et al. in 2010, who first described spadin as a natural antidepressant-type TREK-1 blocker. Importantly, every result is preclinical and in animals. There are no completed or published human efficacy or safety trials of PE-22-28, and it is not an approved drug anywhere. Claims that it treats depression, anxiety, or cognitive decline in people go well beyond what the evidence supports. | There is no peer-reviewed clinical or preclinical literature on Adamax under that name that stands up to a search. What exists is a substantial Russian-language research base on Semax, its parent, which includes clinical use in Russia for stroke recovery, cognitive impairment and optic nerve conditions, and which supports the BDNF and NGF mechanism. Extending that evidence to Adamax requires assuming the analog behaves like the parent, and no published work confirms that assumption. Everything circulating about Adamax's potency relative to Semax is vendor claim and user report, not measurement. The honest position is that this is an uncharacterized research compound whose parent has real but largely non-Western evidence behind it. If you want the compound with actual literature, that compound is Semax. |
Frequently Asked Questions: PE-22-28 vs Adamax
What is the difference between PE-22-28 and Adamax?
PE-22-28 is a cognitive peptide that pe-22-28 is a seven-amino-acid peptide that blocks a potassium channel in the brain called trek-1, the same target tied to depression. it is a shortened, more potent and more stable version of spadin, a natural fragment cut from the sortilin propeptide, and it was built to act like a fast antidepressant. all evidence is from rodents. there are no human clinical trials. Adamax is a cognitive peptide that adamax is sold widely as an enhanced semax derivative, and it is one of the clearest examples of a compound where availability has run far ahead of information. vendors list it, forums discuss it, and there is essentially no peer-reviewed literature under this name. this page tells you what is actually known, what is inferred from its parent compound, and where the honest gaps are, because pretending otherwise would not help you. The main differences lie in their mechanisms of action and clinical applications.
Which is better, PE-22-28 or Adamax?
Neither is universally "better" - the choice depends on your specific goals. PE-22-28 is typically used for cognitive purposes, while Adamax is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can PE-22-28 and Adamax be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using PE-22-28 and Adamax together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.